Hikma Pharmaceuticals (LSE:HIK) Long-Term Debt : £480 Mil (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Long-Term Debt?

Hikma Pharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2024 was £480 Mil.

Hikma Pharmaceuticals's quarterly Long-Term Debt increased from Dec. 2023 (£770 Mil) to Jun. 2024 (£799 Mil) but then declined from Jun. 2024 (£799 Mil) to Dec. 2024 (£480 Mil).

Hikma Pharmaceuticals's annual Long-Term Debt declined from Dec. 2022 (£882 Mil) to Dec. 2023 (£770 Mil) and declined from Dec. 2023 (£770 Mil) to Dec. 2024 (£480 Mil).

Hikma Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Hikma Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Long-Term Debt Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

514.85

489.55

881.75

770.25

480.14

Hikma Pharmaceuticals Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															881.75	817.34	770.25	799.36	480.14

Hikma Pharmaceuticals (LSE:HIK) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Hikma Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines